RS62034B1 - Kompozicije za lečenje raka - Google Patents

Kompozicije za lečenje raka

Info

Publication number
RS62034B1
RS62034B1 RS20210531A RSP20210531A RS62034B1 RS 62034 B1 RS62034 B1 RS 62034B1 RS 20210531 A RS20210531 A RS 20210531A RS P20210531 A RSP20210531 A RS P20210531A RS 62034 B1 RS62034 B1 RS 62034B1
Authority
RS
Serbia
Prior art keywords
cancer
day
hydroxylase
abiraterone acetate
compositions
Prior art date
Application number
RS20210531A
Other languages
English (en)
Serbian (sr)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62034(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of RS62034B1 publication Critical patent/RS62034B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20210531A 2006-08-25 2007-08-23 Kompozicije za lečenje raka RS62034B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
EP12160586.9A EP2478907B1 (en) 2006-08-25 2007-08-23 Compositions for treating cancer

Publications (1)

Publication Number Publication Date
RS62034B1 true RS62034B1 (sr) 2021-07-30

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20210531A RS62034B1 (sr) 2006-08-25 2007-08-23 Kompozicije za lečenje raka
RS20130401A RS52956B (sr) 2006-08-25 2007-08-23 Kompozicije za tretman kancera

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20130401A RS52956B (sr) 2006-08-25 2007-08-23 Kompozicije za tretman kancera

Country Status (20)

Country Link
EP (3) EP3804730A1 (https=)
JP (10) JP2010501575A (https=)
KR (4) KR20200125776A (https=)
CN (2) CN104306977A (https=)
AU (6) AU2007287098C1 (https=)
CA (1) CA2661422C (https=)
CY (2) CY1115477T1 (https=)
DK (2) DK2061561T3 (https=)
ES (2) ES2869343T3 (https=)
HR (2) HRP20130961T1 (https=)
HU (1) HUE054495T2 (https=)
IL (3) IL197211A0 (https=)
LT (1) LT2478907T (https=)
NO (2) NO20091190L (https=)
NZ (1) NZ597830A (https=)
PL (2) PL2061561T3 (https=)
PT (2) PT2478907T (https=)
RS (2) RS62034B1 (https=)
SI (2) SI2478907T1 (https=)
WO (1) WO2008024484A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804730A1 (en) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
AR069079A1 (es) * 2007-10-29 2009-12-30 Takeda Pharmaceutical Farmaco para la prevencion o el tratamiento de cancer
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
ES2863500T3 (es) * 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
WO2018191141A1 (en) * 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
EP1276482B1 (en) * 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2003274823A1 (en) * 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
JP2006515623A (ja) * 2003-01-13 2006-06-01 セダーズ−シナイ メディカル センター 化学療法剤としてのパリカルシトール
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer

Also Published As

Publication number Publication date
EP3804730A1 (en) 2021-04-14
JP6445123B2 (ja) 2018-12-26
KR20090059126A (ko) 2009-06-10
LT2478907T (lt) 2021-06-25
PT2061561E (pt) 2013-10-09
WO2008024484A1 (en) 2008-02-28
PL2478907T3 (pl) 2021-10-25
EP2061561A1 (en) 2009-05-27
JP2019059750A (ja) 2019-04-18
JP6740497B2 (ja) 2020-08-12
CY1124221T1 (el) 2022-05-27
CA2661422C (en) 2017-06-27
HUE054495T2 (hu) 2021-09-28
AU2017201764A1 (en) 2017-04-06
JP2012082215A (ja) 2012-04-26
NO20091190L (no) 2009-03-20
HRP20130961T1 (hr) 2013-11-22
NZ597830A (en) 2013-02-22
NO20200775A1 (no) 2009-03-20
SI2061561T1 (sl) 2013-11-29
HK1131577A1 (en) 2010-01-29
DK2061561T3 (da) 2013-10-07
RS52956B (sr) 2014-02-28
AU2022206696A1 (en) 2022-08-11
ES2428634T3 (es) 2013-11-08
JP2017052791A (ja) 2017-03-16
CN101528308A (zh) 2009-09-09
EP2478907A3 (en) 2012-08-01
JP2018065859A (ja) 2018-04-26
IL257681A (en) 2018-04-30
AU2007287098C1 (en) 2018-03-15
AU2015221447A1 (en) 2015-09-17
PL2061561T3 (pl) 2013-12-31
CY1115477T1 (el) 2017-01-04
JP2021038252A (ja) 2021-03-11
AU2007287098B2 (en) 2013-08-15
KR20180003636A (ko) 2018-01-09
JP2015110577A (ja) 2015-06-18
AU2021201649A1 (en) 2021-04-08
EP2478907A2 (en) 2012-07-25
KR20150108946A (ko) 2015-09-30
EP2478907B1 (en) 2021-04-14
AU2015221447B9 (en) 2017-07-20
JP2024164147A (ja) 2024-11-26
JP2020114851A (ja) 2020-07-30
CN104306977A (zh) 2015-01-28
JP2022185091A (ja) 2022-12-13
SI2478907T1 (sl) 2021-08-31
IL197211A0 (en) 2009-12-24
ES2869343T3 (es) 2021-10-25
DK2478907T3 (da) 2021-05-25
AU2015221447B2 (en) 2016-12-15
JP6053279B2 (ja) 2016-12-27
AU2018271331A1 (en) 2018-12-20
JP2010501575A (ja) 2010-01-21
KR20200125776A (ko) 2020-11-04
IL227746A0 (en) 2013-09-30
HRP20210670T1 (hr) 2021-06-11
CA2661422A1 (en) 2008-02-28
PT2478907T (pt) 2021-05-26
EP2061561B1 (en) 2013-07-10
AU2007287098A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
RS62034B1 (sr) Kompozicije za lečenje raka
Kozin et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
CN101624414B (zh) 一种抑制血管新生的硝酸酯药物
CN101669941B (zh) 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
WO2018229134A1 (en) Tinostamustine for use in treating ovarian cancer
EP3638228A1 (en) Compounds for treating tnbc
CN111386113A (zh) 包含lsz102和阿培利司的药物组合
EP2670405B1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
JP2019513828A (ja) 改善された薬物動態を有するイソフラボノイド組成物
JP2006513223A (ja) ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
HK1131577B (en) Compositions for treating cancer
ES2310182T3 (es) 7-hidroxiepiandrosterona con actividad neuroprotectora.
HK1173966B (en) Compositions for treating cancer
CN114569545B (zh) 一种稳定的米托蒽醌制剂
CN107007611A (zh) 醋酸诺美孕酮在制备治疗子宫内膜癌的药物中的应用
US20030158168A1 (en) Composition for combined use of aromatase inhibitors
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
Landström et al. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma
US20230364053A1 (en) Pharmaceutical composition for treatment of prostate cancer or breast cancer
WO2023172909A1 (en) Compositions comprising anti-progestins and selective estrogen receptor modulators and methods of using the same
US20220354815A1 (en) Okn-007 as a therapeutic agent
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
Kim et al. Hormonal Anticancer Drugs
CN118019537A (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途